Jaguar Health Inc. announced that an abstract describing partial results from an ongoing investigator-initiated trial of crofelemer for pediatric intestinal failure will be presented on November 8, 2025, at the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Annual Meeting. The trial, conducted in the United Arab Emirates, includes patients with intestinal failure due to microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF). Initial findings from the proof-of-concept study indicate that crofelemer use resulted in a reduction of total parenteral support requirements by 12% to 37% in participating pediatric patients. The company is continuing to support additional clinical and expanded access programs for crofelemer in the U.S. and internationally.